ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
1
views
0
references
Top references
cited by
5
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
332
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Medicare and erythropoietin.
Author(s):
Robert Steinbrook
Publication date:
2007-01-04
Journal:
The New England journal of medicine
Keywords:
Erythropoietin
,
economics
,
therapeutic use
,
Health Care Reform
,
legislation & jurisprudence
,
Health Expenditures
,
trends
,
Health Services Misuse
,
Hemoglobins
,
Humans
,
Kidney Failure, Chronic
,
blood
,
therapy
,
Medicare
,
Recombinant Proteins
,
Reimbursement Mechanisms
,
Renal Dialysis
,
United States
Read this article at
ScienceOpen
Publisher
PubMed
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Drug_transporters
Author and article information
Journal
PubMed ID::
17202449
DOI::
10.1056/NEJMp068296
ScienceOpen disciplines:
Chemistry
Keywords:
Erythropoietin
,
economics
,
therapeutic use
,
Health Care Reform
,
legislation & jurisprudence
,
Health Expenditures
,
trends
,
Health Services Misuse
,
Hemoglobins
,
Humans
,
Kidney Failure, Chronic
,
blood
,
therapy
,
Medicare
,
Recombinant Proteins
,
Reimbursement Mechanisms
,
Renal Dialysis
,
United States
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Erythropoietin
,
economics
,
therapeutic use
,
Health Care Reform
,
legislation & jurisprudence
,
Health Expenditures
,
trends
,
Health Services Misuse
,
Hemoglobins
,
Humans
,
Kidney Failure, Chronic
,
blood
,
therapy
,
Medicare
,
Recombinant Proteins
,
Reimbursement Mechanisms
,
Renal Dialysis
,
United States
Comments
Comment on this article
Sign in to comment
scite_
Similar content
332
Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis
Authors:
Tanita Thaweethamcharoen
,
Rungpetch Sakulbumrungsil
,
Cherdchai Nopmaneejumruslers
…
Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Authors:
Huseyin Naci
,
Gregory de Lissovoy
,
Christopher Hollenbeak
…
Neighborhood Greenness and Chronic Health Conditions in Medicare Beneficiaries.
Authors:
Scott C. Brown
,
Joanna L. Lombard
,
Kefeng Wang
…
See all similar
Cited by
5
Influence of learning styles on the practical performance after the four-step basic life support training approach – An observational cohort study
Authors:
Hanna Schröder
,
Alexandra Henke
,
Lina Stieger
…
Erythropoietin use and abuse
Authors:
M. John
,
Vineeth Jaison
,
Kunal Jain
…
Erythropoietin treatment and the risk of hip fractures in hemodialysis patients
Authors:
Sukanya Suresh
,
Elizabeth C Wright
,
Daniel Wright
…
See all cited by